---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-037794"
form_type: "8-K"
ticker: "ENSC"
cik: "0001716947"
company_name: "Ensysce Biosciences, Inc."
filed_at: "2026-08-13T20:20:20+00:00"
generated_at: "2026-08-13T20:21:11.226321+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Ensysce Q2 net loss $2.6M; completes Cy Biopharma acquisition adding CY200, $77M funding

## Summary
- Completed acquisition of Cy Biopharma on Aug 6, 2026, adding CY200 (Orphan Drug-designated for CRPS) as lead asset; up to $77M in new funding.
- Q2 2026 net loss $2.6M vs $1.7M; cash $0.7M at June 30, 2026 vs $4.3M at Dec 31, 2025.
- Post-quarter-end acquisition and financings provided ~$31M net cash; runway into late 2027, second tranche up to $38.6M on milestones.
- R&D expenses $2.5M (up from $1.9M); federal grants $1.2M; NIDA grant third year awarded, total $26M over six years.
- Taiwan patent for MPAR through 2042; PF614-301 Phase 3 trial ongoing.

## SEC filing metadata
- accession: 0001493152-26-037794
- form_type: 8-K
- ticker: ENSC
- cik: 0001716947
- company_name: Ensysce Biosciences, Inc.
- filed_at: 2026-08-13T20:20:20+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1716947/000149315226037794/0001493152-26-037794-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1716947/000149315226037794/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-037794
- JSON: https://secwatch.observer/filing/0001493152-26-037794.json
- Plain text: https://secwatch.observer/filing/0001493152-26-037794.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.